Reliv International, Inc (NASDAQ:RELV) reported net sales of $14.5 million for the first quarter of 2014, compared to net sales of $18.9 million for the first quarter of 2013. Net sales in the United States declined by 29.2 percent for the quarter compared to the same quarter in 2013. Reliv International, Inc (NASDAQ:RELV) stock performance was 7.37% in last session and finished the day at $ 2.04. Traded volume was 14,298 shares in the last session and the average volume of the stock remained 15,554. The beta of the stock remained 2.95. Reliv International, Inc (NASDAQ:RELV) insider ownership is 0.20%.

Flexion Therapeutics Inc (NASDAQ:FLXN announced that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. FX006 is Flexion’s novel, non-opioid, sustained-release, intra-articular (IA) formulation of triamcinolone acetonide (TCA).Flexion Therapeutics Inc (NASDAQ:FLXN)Rose 5.52% percent to $ 12.81 yesterday on volume of 37,028 shares. The intra-day range of the stock was $ 12.00 – 13.43. Flexion Therapeutics Inc (NASDAQ:FLXN) has a market capitalization of $ 199.95 million.

Relypsa Inc (NASDAQ:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 13, 2014 at 5:00 pm PT. Relypsa Inc (NASDAQ:RLYP)’s stock on May 7, 2014 reported a increase 6.77% to the closing price of $ 21.45. Its fifty two weeks range is $ 11.55 – 52.74. The total market capitalization recorded $ 637.37 million. The overall volume in the last trading session was 170,644 shares. In its share capital, Relypsa Inc(NASDAQ:RLYP) has 33.84 million outstanding shares.

Sucampo Pharmaceuticals (NASDAQ:SCMP) is scheduled to be announcing its Q113 earnings results on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $24.19 million for the quarter. On Friday, shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)advanced 7.51% to close the day at $ 7.30. Company return on investment (ROI) is 4.80% and its monthly performance is recorded as 3.84%. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) quarterly revenue growth is -3.95%.